

# Drugs for Non-small Cell Lung Cancer-China Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/DCAFC8C1C2CMEN.html>

Date: May 2018

Pages: 158

Price: US\$ 2,980.00 (Single User License)

ID: DCAFC8C1C2CMEN

## Abstracts

### Report Summary

Drugs for Non-small Cell Lung Cancer-China Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Drugs for Non-small Cell Lung Cancer industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole China and Regional Market Size of Drugs for Non-small Cell Lung Cancer 2013-2017, and development forecast 2018-2023

Main market players of Drugs for Non-small Cell Lung Cancer in China, with company and product introduction, position in the Drugs for Non-small Cell Lung Cancer market  
Market status and development trend of Drugs for Non-small Cell Lung Cancer by types and applications

Cost and profit status of Drugs for Non-small Cell Lung Cancer, and marketing status  
Market growth drivers and challenges

The report segments the China Drugs for Non-small Cell Lung Cancer market as:

China Drugs for Non-small Cell Lung Cancer Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North China

Northeast China

East China  
Central & South China  
Southwest China  
Northwest China

China Drugs for Non-small Cell Lung Cancer Market: Product Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Radiofrequency Ablation (RFA)  
Radiation Therapy  
Chemotherapy  
Targeted Therapies  
Immunotherapy

China Drugs for Non-small Cell Lung Cancer Market: Application Segment Analysis  
(Consumption Volume and Market Share 2013-2023; Downstream Customers and  
Market Analysis)

Hospital  
Clinic  
Other

China Drugs for Non-small Cell Lung Cancer Market: Players Segment Analysis  
(Company and Product introduction, Drugs for Non-small Cell Lung Cancer Sales  
Volume, Revenue, Price and Gross Margin):

Bristol-Myers Squibb  
GlaxoSmithKline  
Menarini  
Sanofi  
Ziopharm Oncology  
Alchemia  
Amgen  
Apotex  
BioMarin Pharmaceutical  
CellAct Pharma  
Cerulean Pharma  
Cipla  
Cornerstone Pharmaceuticals

Curis  
CytRx  
Eli Lilly  
Exelixis  
Fresenius Kabi  
Genentech  
Hikma Pharmaceuticals  
Hospira  
Intas Pharmaceuticals  
Karyopharm Therapeutics  
Kyowa Hakko Kirin  
Ligand Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF DRUGS FOR NON-SMALL CELL LUNG CANCER**

- 1.1 Definition of Drugs for Non-small Cell Lung Cancer in This Report
- 1.2 Commercial Types of Drugs for Non-small Cell Lung Cancer
  - 1.2.1 Radiofrequency Ablation (RFA)
  - 1.2.2 Radiation Therapy
  - 1.2.3 Chemotherapy
  - 1.2.4 Targeted Therapies
  - 1.2.5 Immunotherapy
- 1.3 Downstream Application of Drugs for Non-small Cell Lung Cancer
  - 1.3.1 Hospital
  - 1.3.2 Clinic
  - 1.3.3 Other
- 1.4 Development History of Drugs for Non-small Cell Lung Cancer
- 1.5 Market Status and Trend of Drugs for Non-small Cell Lung Cancer 2013-2023
  - 1.5.1 India Drugs for Non-small Cell Lung Cancer Market Status and Trend 2013-2023
  - 1.5.2 Regional Drugs for Non-small Cell Lung Cancer Market Status and Trend 2013-2023

### **CHAPTER 2 INDIA MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Drugs for Non-small Cell Lung Cancer in India 2013-2017
- 2.2 Consumption Market of Drugs for Non-small Cell Lung Cancer in India by Regions
  - 2.2.1 Consumption Volume of Drugs for Non-small Cell Lung Cancer in India by Regions
  - 2.2.2 Revenue of Drugs for Non-small Cell Lung Cancer in India by Regions
- 2.3 Market Analysis of Drugs for Non-small Cell Lung Cancer in India by Regions
  - 2.3.1 Market Analysis of Drugs for Non-small Cell Lung Cancer in North India 2013-2017
  - 2.3.2 Market Analysis of Drugs for Non-small Cell Lung Cancer in Northeast India 2013-2017
  - 2.3.3 Market Analysis of Drugs for Non-small Cell Lung Cancer in East India 2013-2017
  - 2.3.4 Market Analysis of Drugs for Non-small Cell Lung Cancer in South India 2013-2017
  - 2.3.5 Market Analysis of Drugs for Non-small Cell Lung Cancer in West India 2013-2017

## 2.4 Market Development Forecast of Drugs for Non-small Cell Lung Cancer in India 2017-2023

### 2.4.1 Market Development Forecast of Drugs for Non-small Cell Lung Cancer in India 2017-2023

### 2.4.2 Market Development Forecast of Drugs for Non-small Cell Lung Cancer by Regions 2017-2023

## **CHAPTER 3 INDIA MARKET STATUS AND FORECAST BY TYPES**

### 3.1 Whole India Market Status by Types

#### 3.1.1 Consumption Volume of Drugs for Non-small Cell Lung Cancer in India by Types

#### 3.1.2 Revenue of Drugs for Non-small Cell Lung Cancer in India by Types

### 3.2 India Market Status by Types in Major Countries

#### 3.2.1 Market Status by Types in North India

#### 3.2.2 Market Status by Types in Northeast India

#### 3.2.3 Market Status by Types in East India

#### 3.2.4 Market Status by Types in South India

#### 3.2.5 Market Status by Types in West India

### 3.3 Market Forecast of Drugs for Non-small Cell Lung Cancer in India by Types

## **CHAPTER 4 INDIA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

### 4.1 Demand Volume of Drugs for Non-small Cell Lung Cancer in India by Downstream Industry

### 4.2 Demand Volume of Drugs for Non-small Cell Lung Cancer by Downstream Industry in Major Countries

#### 4.2.1 Demand Volume of Drugs for Non-small Cell Lung Cancer by Downstream Industry in North India

#### 4.2.2 Demand Volume of Drugs for Non-small Cell Lung Cancer by Downstream Industry in Northeast India

#### 4.2.3 Demand Volume of Drugs for Non-small Cell Lung Cancer by Downstream Industry in East India

#### 4.2.4 Demand Volume of Drugs for Non-small Cell Lung Cancer by Downstream Industry in South India

#### 4.2.5 Demand Volume of Drugs for Non-small Cell Lung Cancer by Downstream Industry in West India

### 4.3 Market Forecast of Drugs for Non-small Cell Lung Cancer in India by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF DRUGS FOR NON-SMALL CELL LUNG CANCER**

5.1 India Economy Situation and Trend Overview

5.2 Drugs for Non-small Cell Lung Cancer Downstream Industry Situation and Trend Overview

## **CHAPTER 6 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET COMPETITION STATUS BY MAJOR PLAYERS IN INDIA**

6.1 Sales Volume of Drugs for Non-small Cell Lung Cancer in India by Major Players

6.2 Revenue of Drugs for Non-small Cell Lung Cancer in India by Major Players

6.3 Basic Information of Drugs for Non-small Cell Lung Cancer by Major Players

6.3.1 Headquarters Location and Established Time of Drugs for Non-small Cell Lung Cancer Major Players

6.3.2 Employees and Revenue Level of Drugs for Non-small Cell Lung Cancer Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

## **CHAPTER 7 DRUGS FOR NON-SMALL CELL LUNG CANCER MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

7.1 Bristol-Myers Squibb

7.1.1 Company profile

7.1.2 Representative Drugs for Non-small Cell Lung Cancer Product

7.1.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb

7.2 GlaxoSmithKline

7.2.1 Company profile

7.2.2 Representative Drugs for Non-small Cell Lung Cancer Product

7.2.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of GlaxoSmithKline

7.3 Menarini

7.3.1 Company profile

7.3.2 Representative Drugs for Non-small Cell Lung Cancer Product

7.3.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Menarini

7.4 Sanofi

7.4.1 Company profile

7.4.2 Representative Drugs for Non-small Cell Lung Cancer Product

7.4.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Sanofi

7.5 Ziopharm Oncology

7.5.1 Company profile

7.5.2 Representative Drugs for Non-small Cell Lung Cancer Product

7.5.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Ziopharm Oncology

7.6 Alchemia

7.6.1 Company profile

7.6.2 Representative Drugs for Non-small Cell Lung Cancer Product

7.6.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Alchemia

7.7 Amgen

7.7.1 Company profile

7.7.2 Representative Drugs for Non-small Cell Lung Cancer Product

7.7.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Amgen

7.8 Apotex

7.8.1 Company profile

7.8.2 Representative Drugs for Non-small Cell Lung Cancer Product

7.8.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Apotex

7.9 BioMarin Pharmaceutical

7.9.1 Company profile

7.9.2 Representative Drugs for Non-small Cell Lung Cancer Product

7.9.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of BioMarin Pharmaceutical

7.10 CellAct Pharma

7.10.1 Company profile

7.10.2 Representative Drugs for Non-small Cell Lung Cancer Product

7.10.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of CellAct Pharma

7.11 Cerulean Pharma

7.11.1 Company profile

- 7.11.2 Representative Drugs for Non-small Cell Lung Cancer Product
- 7.11.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Cerulean Pharma
- 7.12 Cipla
  - 7.12.1 Company profile
  - 7.12.2 Representative Drugs for Non-small Cell Lung Cancer Product
  - 7.12.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Cipla
- 7.13 Cornerstone Pharmaceuticals
  - 7.13.1 Company profile
  - 7.13.2 Representative Drugs for Non-small Cell Lung Cancer Product
  - 7.13.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Cornerstone Pharmaceuticals
- 7.14 Curis
  - 7.14.1 Company profile
  - 7.14.2 Representative Drugs for Non-small Cell Lung Cancer Product
  - 7.14.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Curis
- 7.15 CytRx
  - 7.15.1 Company profile
  - 7.15.2 Representative Drugs for Non-small Cell Lung Cancer Product
  - 7.15.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of CytRx
- 7.16 Eli Lilly
- 7.17 Exelixis
- 7.18 Fresenius Kabi
- 7.19 Genentech
- 7.20 Hikma Pharmaceuticals
- 7.21 Hospira
- 7.22 Intas Pharmaceuticals
- 7.23 Karyopharm Therapeutics
- 7.24 Kyowa Hakko Kirin
- 7.25 Ligand Pharmaceuticals

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF DRUGS FOR NON-SMALL CELL LUNG CANCER**

- 8.1 Industry Chain of Drugs for Non-small Cell Lung Cancer
- 8.2 Upstream Market and Representative Companies Analysis



### 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF DRUGS FOR NON-SMALL CELL LUNG CANCER**

### 9.1 Cost Structure Analysis of Drugs for Non-small Cell Lung Cancer

### 9.2 Raw Materials Cost Analysis of Drugs for Non-small Cell Lung Cancer

### 9.3 Labor Cost Analysis of Drugs for Non-small Cell Lung Cancer

### 9.4 Manufacturing Expenses Analysis of Drugs for Non-small Cell Lung Cancer

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF DRUGS FOR NON-SMALL CELL LUNG CANCER**

### 10.1 Marketing Channel

#### 10.1.1 Direct Marketing

#### 10.1.2 Indirect Marketing

#### 10.1.3 Marketing Channel Development Trend

### 10.2 Market Positioning

#### 10.2.1 Pricing Strategy

#### 10.2.2 Brand Strategy

#### 10.2.3 Target Client

### 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

### 12.1 Methodology/Research Approach

#### 12.1.1 Research Programs/Design

#### 12.1.2 Market Size Estimation

#### 12.1.3 Market Breakdown and Data Triangulation

### 12.2 Data Source

#### 12.2.1 Secondary Sources

#### 12.2.2 Primary Sources

### 12.3 Reference

## I would like to order

Product name: Drugs for Non-small Cell Lung Cancer-China Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/DCAFC8C1C2CMEN.html>

Price: US\$ 2,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DCAFC8C1C2CMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970